Literature DB >> 11912107

Minocycline prevents neurotoxicity induced by cerebrospinal fluid from patients with motor neurone disease.

Tiina M Tikka1, Nina E Vartiainen, Gundars Goldsteins, Simo S Oja, Peter M Andersen, Stefan L Marklund, Jari Koistinaho.   

Abstract

CSF from patients with motor neurone disease (MND) has been reported to be toxic to cultured primary neurones. We found that CSF from MND patients homozygous for the D90A CuZn-superoxide dismutase (CuZn-SOD) mutation, patients with sporadic MND and patients with familial MND without CuZn-SOD mutations significantly increased apoptosis and reduced phosphorylation of neurofilaments in cultured spinal cord neurones when compared with the effects of CSF from patients with other neurological diseases. Exposure of spinal cord cultures to MND CSF also triggered microglial activation. The toxicity of MND CSF was independent of the presence of the CuZn-SOD mutation, and it did not correlate with gelatinase activity or the presence of immunoglobulin G autoantibodies in the CSF. The concentrations of glutamate, aspartate and glycine in MND CSF were not elevated. Antagonists of N-methyl-D-aspartate (NMDA) and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid/kainate receptors prevented the toxic CSF-induced neuronal death but not microglial activation, whereas minocycline, a tetracycline derivative with anti-inflammatory potential independent of antimicrobial activity, reduced both the apoptotic neuronal death and microglial activation. We conclude that the cytotoxic action of CSF is prevalent in all MND cases and that microglia may mediate the toxicity of CSF by releasing excitotoxicity-enhancing factors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11912107     DOI: 10.1093/brain/awf068

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  35 in total

Review 1.  Stem cell-derived motor neurons: applications and challenges in amyotrophic lateral sclerosis.

Authors:  Jason R Thonhoff; Luis Ojeda; Ping Wu
Journal:  Curr Stem Cell Res Ther       Date:  2009-09       Impact factor: 3.828

Review 2.  Neurobiology of injury to the developing brain.

Authors:  Wenbin Deng
Journal:  Nat Rev Neurol       Date:  2010-05-18       Impact factor: 42.937

3.  Minocycline attenuates HIV-1 infection and suppresses chronic immune activation in humanized NOD/LtsZ-scidIL-2Rγ(null) mice.

Authors:  Maneesh Singh; Pratibha Singh; Dolores Vaira; Mathieu Amand; Souad Rahmouni; Michel Moutschen
Journal:  Immunology       Date:  2014-08       Impact factor: 7.397

Review 4.  Inflammation in the early stages of neurodegenerative pathology.

Authors:  Preeti J Khandelwal; Alexander M Herman; Charbel E-H Moussa
Journal:  J Neuroimmunol       Date:  2011-08-05       Impact factor: 3.478

Review 5.  Clinical genetics of amyotrophic lateral sclerosis: what do we really know?

Authors:  Peter M Andersen; Ammar Al-Chalabi
Journal:  Nat Rev Neurol       Date:  2011-10-11       Impact factor: 42.937

6.  Reduced PBR/TSPO expression after minocycline treatment in a rat model of focal cerebral ischemia: a PET study using [(18)F]DPA-714.

Authors:  Abraham Martín; Raphaël Boisgard; Michael Kassiou; Frédéric Dollé; Bertrand Tavitian
Journal:  Mol Imaging Biol       Date:  2011-02       Impact factor: 3.488

7.  Targeting neuro-inflammatory cytokines and oxidative stress by minocycline attenuates quinolinic-acid-induced Huntington's disease-like symptoms in rats.

Authors:  Harikesh Kalonia; Jitendriya Mishra; Anil Kumar
Journal:  Neurotox Res       Date:  2012-03-06       Impact factor: 3.911

Review 8.  Minocycline: far beyond an antibiotic.

Authors:  N Garrido-Mesa; A Zarzuelo; J Gálvez
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

Review 9.  TRPM7 and TRPM2-Candidate susceptibility genes for Western Pacific ALS and PD?

Authors:  Meredith C Hermosura; Ralph M Garruto
Journal:  Biochim Biophys Acta       Date:  2007-02-24

10.  Does neuroinflammation fan the flame in neurodegenerative diseases?

Authors:  Tamy C Frank-Cannon; Laura T Alto; Fiona E McAlpine; Malú G Tansey
Journal:  Mol Neurodegener       Date:  2009-11-16       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.